A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension

Annals of the Rheumatic Diseases
Sébastien SangesM Humbert

Abstract

Despite the wide use of the 6 min walk distance (6MWD), no study has ever assessed its validity as a surrogate marker for haemodynamics and predictor of outcome in isolated pulmonary arterial hypertension associated with systemic sclerosis (SSc-PAH). We designed this work to address this issue. Treatment-naïve patients with SSc-PAH were prospectively included from two sources: the French PAH Network (a prospective epidemiological cohort) (n=83) and randomised clinical trials submitted for drug approval (Food and Drug Administration) (n=332). Correlations between absolute values of the 6MWD and haemodynamics at baseline, as well as between variations of 6MWD and haemodynamics during follow-up, were studied in both populations. In the French cohort, baseline cardiac output (CO) (R(2)=0.19, p=0.001) and New York Heart Association class (R(2)=0.10, p<0.001) were significantly and independently correlated with baseline 6MWD in multivariate analysis. A significant, independent, but weaker, correlation with CO was also found in the Food and Drug Administration sample (R(2)=0.04, p<0.001). During follow-up, there was no association between the changes in 6MWD and haemodynamic parameters in patients under PAH-specific treatments. In SSc...Continue Reading

References

Feb 1, 1988·Postgraduate Medical Journal·A J BarnettG O Littlejohn
May 29, 1982·British Medical Journal·R J ButlandD M Geddes
Nov 17, 1998·American Journal of Respiratory and Critical Care Medicine·P L Enright, D L Sherrill
Mar 19, 2002·American Journal of Respiratory and Critical Care Medicine·Gerald SimonneauUNKNOWN Treprostinil Study Group
Mar 22, 2002·The New England Journal of Medicine·Lewis J RubinGerald Simonneau
Jul 2, 2002·American Journal of Respiratory and Critical Care Medicine·UNKNOWN ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories
Aug 2, 2002·The New England Journal of Medicine·Horst OlschewskiUNKNOWN Aerosolized Iloprost Randomized Study Group
Sep 3, 2002·Journal of the American College of Cardiology·Olivier SitbonGérald Simonneau
Nov 25, 2003·American Journal of Respiratory and Critical Care Medicine·Robyn J BarstUNKNOWN STRIDE-1 Study Group
Nov 18, 2005·The New England Journal of Medicine·Nazzareno GalièUNKNOWN Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group
May 16, 2006·Journal of the American College of Cardiology·Robyn J BarstUNKNOWN STRIDE-2 Study Group
Aug 22, 2006·European Journal of Clinical Investigation·K Ahmadi-SimabW L Gross
Mar 3, 2007·Annals of the Rheumatic Diseases·Virginia D Steen, Thomas A Medsger
Mar 29, 2008·American Journal of Respiratory and Critical Care Medicine·Nicole S L GohAthol U Wells
May 29, 2008·Circulation·Nazzareno GalièUNKNOWN Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies
Feb 12, 2009·The Journal of Rheumatology·Margaret C GarinCharlie Strange
Jun 3, 2009·The Journal of Rheumatology·Yoland SchoindreYannick Allanore
Feb 10, 2010·Clinical Reviews in Allergy & Immunology·Eric Hachulla, David Launay
Feb 16, 2010·Respiratory Medicine·Horst OlschewskiWerner Seeger
Mar 3, 2010·American Journal of Respiratory and Critical Care Medicine·Jérôme Le PavecPaul M Hassoun
Mar 27, 2010·American Journal of Respiratory and Critical Care Medicine·Aránzazu CampoPaul M Hassoun
Apr 29, 2010·Current Rheumatology Reports·Nadera J SweissStephen L Archer
Jun 22, 2010·The European Respiratory Journal·M HumbertUNKNOWN French Pulmonary Arterial Hypertension Network
Dec 2, 2010·European Respiratory Review : an Official Journal of the European Respiratory Society·E Hachulla, C P Denton
Nov 15, 2011·Pulmonary Pharmacology & Therapeutics·Julio SandovalUNKNOWN STRIDE-4 investigators
Sep 22, 2012·Journal of the American College of Cardiology·Gianluigi SavaresePasquale Perrone-Filardi
Nov 28, 2012·Annals of the Rheumatic Diseases·David LaunayMarc Humbert
Dec 1, 2012·Science Translational Medicine·Elizabeth A MartinRonald G Victor
Jul 26, 2013·The New England Journal of Medicine·Hossein-Ardeschir GhofraniUNKNOWN PATENT-1 Study Group
Jun 22, 2014·Circulation·Corey E VentetuoloSteven M Kawut

❮ Previous
Next ❯

Citations

Dec 17, 2017·Arthritis Research & Therapy·Sébastien SangesDavid Launay
Jul 3, 2018·The Journal of Rheumatology·Grégory PugnetDominique Farge
Dec 6, 2017·Expert Review of Clinical Immunology·Fabiola AtzeniPiercarlo Sarzi-Puttini
May 14, 2017·Respirology : Official Journal of the Asian Pacific Society of Respirology·Matthew R LammiUNKNOWN PHAROS Investigators
Jun 10, 2021·American Journal of Respiratory and Critical Care Medicine·Kristofer AndréassonElizabeth R Volkmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.